Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


LiDCO launches rapid monitoring system in Europe and US

This article was originally published in Clinica

Executive Summary

LiDCO has launched its latest haemodynamic monitor, LiDCOrapid, in the US and EU. The product received US 510(k) clearance and was CE marked for sale in Europe last week. Unlike the older LiDCOplus monitor, which was approved in 2003 and is used in the intensive care unit, LiDCOrapid is designed for the operating theatre. The London, UK company said that LiDCOrapid was quicker to set up and easier to use and interpret, so it was more suited to this setting. LiDCOrapid measures various parameters including heart rate, stroke volume and cardiac output, and blood pressures. It will soon be available in Canada, LiDCO said, and other countries where registration is similar or identical to EU requirements.

You may also be interested in...

Coronavirus Update: UK Calls For COVID-19 Patients To Join Trials

Commission Regulatory Advice For COVID-19 Medtech Sector Entrants Amid Counterfeit Concerns

A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.

Commission’s One-Year MDR Delay Text Contains EU-Wide Derogation Proposals Too

The race is now on to get formal adoption of European Commission proposal postponing the MDR by one year and allowing more devices on the market more quickly. But potential hurdles are in the way as experts advise caution.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts